An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade. An open-label phase 2 study to evaluate the safety and efficacy of CCX168in subjects with IgA Nephro ...
An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade. An open-label phase 2 study to evaluate the safety and efficacy of CCX168in subjects with IgA Nephro ...
IgAN is reported as the most common glomerulonephritis worldwide. It is associated with a wide spectrum of disease severity and rate of progression of renal failure. MedDRA version: 17.1;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] IgAN is reported as the most common glomerulonephritis worldwide. It is associated with a wide spect ...
Product Name: CCX168 Other descriptive name: CCX168
An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade. An open-label phase 2 study to evaluate the safety and efficacy of CCX168in subjects with IgA Nephro ...
An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade. An open-label phase 2 study to evaluate the safety and efficacy of CCX168in subjects with IgA Nephro ...
IgAN is reported as the most common glomerulonephritis worldwide. It is associated with a wide spectrum of disease severity and rate of progression of renal failure. MedDRA version: 17.1;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] IgAN is reported as the most common glomerulonephritis worldwide. It is associated with a wide spect ...
Product Name: CCX168 Other descriptive name: CCX168